BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$82.05 USD
+0.22 (0.27%)
Updated May 9, 2024 02:04 PM ET
2-Buy of 5 2
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 501 - 520 ( 812 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan. 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
On the January DMD Docket - A Drisa Decision and Eteplirsen Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - January and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 21st
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
December 2015 and Full-Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 7th
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
One Data Set, Two Conclusions -Summary of the Drisapersen Advisory Committee Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Briefing Documents for Drisapersen Pull No Punches - But What Does it Mean?
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
November and Remaining 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Growth Drivers Intact Despite Q3 Revenue Miss; DM DAdvisory Committee Next Up; Reiterate NEUTRAL and $137 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals: Potential Ripple Effect of Drisapersen''s Advisory Panel
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D